SAN DIEGO, Jan. 12, 2017 /PRNewswire/ -- Trovagene,
Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA)
technologies, today announced that it has signed agreements with
seven strategic partners across Europe and the Middle East for commercialization of the
Trovera™ liquid biopsy tests. This milestone
marks the first wave of international distribution agreements for
Trovagene's CLIA based liquid biopsy tests for urine and blood
samples.
The initial partners will introduce Trovagene's liquid biopsy
tests to physicians, laboratories and cancer centers in key
regional markets. In addition, these partners will have early
access to Trovagene's research use only liquid biopsy kits and
systems to distribute to clinical research facilities in
Europe, Middle East, Africa and Asia.
These strategic partners include Alliance Global (AGBL) for the
Middle East, Africa, Central and South Asia, Instituto Diagnostico Varelli
(Italy), Progenetics (Israel), Amplitech (France, Belgium and Switzerland), NM Genomix (Bulgaria and East
Europe), Diagnostica Longwood (Spain and Portugal), and Sorgente Genetica (Italy).
"We are excited to announce that physicians and patients in
these international markets now have access to our industry leading
laboratory developed tests for EGFR, KRAS, and
BRAF mutations in urine and blood," said Bill Welch, Chief Executive Officer of
Trovagene.
Trovagene is pleased to partner with these premier life science
and diagnostic organizations. In addition to the
well-established clinical next-generation sequencing and research
business channels they have created in their regions, this network
also provides the infrastructure for scientific education, training
and support of new technologies and future product
introductions.
About Trovagene, Inc.
Headquartered in San Diego,
California, Trovagene is leveraging its proprietary
Precision Cancer Monitoring® (PCM) technology in an effort to
enable itself, and others through the distribution of research use
kits and systems, to detect and monitor ctDNA in urine and blood.
The Company's technology allows for detection and quantitation of
oncogene mutations in cancer patients for improved disease
management. Trovagene's PCM technology is designed to provide
important clinical information beyond the current standard of care,
and is protected by significant intellectual property, including
multiple issued patents and pending patent applications globally.
For more information, please visit http://www.trovagene.com/.
Forward-Looking Statements
Certain statements in this press release are forward-looking within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements may be identified by the use of words such
as "anticipate," "believe," "forecast," "estimated" and "intend" or
other similar terms or expressions that concern Trovagene's
expectations, strategy, plans or intentions. These forward-looking
statements are based on Trovagene's current expectations and actual
results could differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated
by such forward-looking statements. These factors include, but are
not limited to, substantial competition; our need for additional
financing; uncertainties of patent protection and litigation;
clinical trials involve a lengthy and expensive process with an
uncertain outcome, and results of earlier studies and trials may
not be predictive of future trial results; uncertainties of
government or fourth party payer reimbursement; limited sales and
marketing efforts and dependence upon fourth parties; our ability
to develop tests, kits and systems and the success of those
products; and risks related to failure to obtain FDA clearances or
approvals and noncompliance with FDA regulations. There are no
guarantees that any of our technologies or products will be
utilized by oncologists or prove to be commercially successful, or
that Trovagene's strategy to design its PCM platform to report on
clinically actionable cancer genes will ultimately be successful or
result in better reimbursement outcomes. Trovagene does not
undertake an obligation to update or revise any forward-looking
statement. Investors should read the risk factors set forth
in Trovagene's Form 10-K for the year ended December 31, 2015 and other periodic reports
filed with the Securities and Exchange Commission.
Trovagene Contacts:
Beth
Anderson
VP, Finance &
Administration
|
|
Vicki
Kelemen
Sr. Director,
Marketing Communications
|
858-952-7593
|
|
858-952-7652
|
ir@trovagene.com
|
|
vkelemen@trovagene.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/trovagene-announces-broadening-network-of-commercial-distributors-300390107.html
SOURCE Trovagene, Inc.